TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06561425

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GLPG5101
Description: Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GLPG5101
Description: Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GLPG5101
Description: Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GLPG5101
Description: Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy
Study: NCT03316183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative and postoperative management
Description: Cerebral oximetry informed perioperative management
Study: NCT05982431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: 60-minutes exercise program, three times a week on alternate days for 12 successive weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: 60-minutes exercise program, three times a week on alternate days for 12 successive weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: 60-minutes exercise program, three times a week on alternate days for 12 successive weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinsio taping
Description: One full strip of kinesiology taping tape and one half-length strip were needed for the kinesiology taping application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo Kinsio taping
Description: One full strip of kinesiology taping tape and one half-length strip were needed for the placebo kinesiology taping application
Study: NCT06561425

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GLPG5101
Description: Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy
Study: NCT05208307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT06115148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding
Description: Nutrition beverages will be provided to meet the nutrient needs described in the Feeding Arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Water will be consumed as described during the Fasting Arm.
Study: NCT05486741

Intervention type: OTHER
Intervention: Optical cehernce tomography
Description: OCT macula and disc

Intervention type: OTHER
Intervention: Optical cehernce tomography
Description: OCT macula and disc

Intervention type: OTHER
Intervention: Optical cehernce tomography
Description: OCT macula and disc
Study: NCT05765981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGN-R09b
Description: VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
Study: NCT05562011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caretaker Device placement
Description: a continuous non-invasive blood pressure and vital signs monitor that is worn on the wrist
Study: NCT06782048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oesophagogastroduodenoscopy (OGD) and biopsy
Description: Study participant will undergo OGD with collection of gastric mucosal biopsies at the baseline visit to ascertain IM status and for molecular analyses. Study participant will undergo follow-up gastroscopy with collection of gastric mucosal biopsies at day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment to assess if endpoint is reached and for molecular analyses. Gastric juice samples will be collected during each OGD.
Study: NCT05526703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D064, D701, placebo of D012
Description: Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D012, placebo of D064, placebo of D701
Description: Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
Study: NCT06782048

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gastric juice, saliva and stool collection and analyses
Description: Gastric juice will be taken, and gastric pH will be measured at each research endoscopy. Saliva and stool will also be obtained from participants at research endoscopy for microbiome studies at the following timepoints: baseline, 6 weeks post-treatment, and 1 year post-treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric juice, saliva and stool collection and analyses
Description: Gastric juice will be taken, and gastric pH will be measured at each research endoscopy. Saliva and stool will also be obtained from participants at research endoscopy for microbiome studies at the following timepoints: baseline, 6 weeks post-treatment, and 1 year post-treatment.
Study: NCT00548106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: partially hydrolyzed whey
Description: Total infant feeding by study formula.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: partially hydrolyzed whey
Description: Total infant feeding by study formula.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nan HA
Description: Total infant diet by study formula.
Study: NCT05351398

Intervention type: DRUG
Intervention: PDO group
Description: Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.

Intervention type: DRUG
Intervention: PDO group
Description: Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.

Intervention type: DRUG
Intervention: Traditional group
Description: Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.

Intervention type: DRUG
Intervention: Traditional group
Description: Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
Study: NCT06780735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The margin-positive rate using the localization technique
Description: Localization of breast cancer using indocyanine green fluorescence (ICG-F)
Study: NCT06779916

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: 16 blood samples (16 tubes, i.e. 55.3 ml) will be taken at inclusion. Pregnant women will be seen every month as part of their pregnancy follow-up, and blood (11 tubes, i.e. 35.5 ml) and urine samples will be taken at each follow-up visit.~At delivery, a systematic blood sample will be taken as part of the usual care, and an additional 11 tubes of blood (35.5 ml) will be taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine test
Description: Urine samples will be taken at the inclusion visit and at each follow-up visit.
Study: NCT05991921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: TENS application, postpartum 10-12. at hours and 14-16. It was applied twice for 30 minutes each. Researcher 1 programmed the TENS unit and was the only researcher who knew whether TENS was active or in placebo mode.~Two pairs of TENS electrodes were placed on the upper and lower border of the cesarean section incision line. A total of 4 electrodes were used in a sterile package for each participant. TENS stimulation was applied at a frequency of 100 Hz and was increased starting from 0 mA. The participant's stimulation was fixed at the mA level, where he felt optimal but did not feel discomfort.~The pretest data were applied to the participants who met the inclusion criteria and volunteered to participate in the study, by the researcher 2 in the patient rooms 10 hours after the cesarean section. Post-test data were obtained by the same investigator 16 hours after cesarean section.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Plasebo-Fake TENS
Description: Participants in the placebo group 10-12 postpartum. at hours and 14-16. Two pairs of TENS electrodes were placed at the same time as the intervention group. TENS electrodes were attached to the participants in this group for 30 minutes, the device was operated but no electric current was applied.
Study: NCT04533477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructing forked corpus spongiosum (FCS)
Description: During the routine standardized surgery, the FCS should be cut off along both sides of the middle urethral plate before dissecting the glans wings and then dissected along the penile tunica albuginea closely from the near to the far side of the penis until the top of the penis head was reached. The corpus spongiosum on both sides will be reserved for the two wings of the glans. The two wings of the glans should be carefully expanded to at least the 3 o'clock and 9 o'clock positions of the penis. Some cases of small glans should be dissected to the 2 o'clock and 10 o'clock positions to close the two wings of the glans with no tension when performing glansplasty. Additionally, the original FCS on both sides should be combined at the coronal sulcus, thereby covering the surface of the new urethra.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine standardized surgery
Description: When the urethral plate can be preserved after degloving, the investigators chose the surgical method according to the width of the urethral plate. If the width of the urethral plate is ≥6 mm, tubularized incised plate (TIP) urethroplasty will be performed, whereas if the width of the urethral plate is \<6 mm, the onlay island flap (ONLAY) technique will be performed. When the urethral plate can not be preserved after degloving, transverse preputial island flap urethroplasty (Duckett) will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine standardized surgery
Description: When the urethral plate can be preserved after degloving, the investigators chose the surgical method according to the width of the urethral plate. If the width of the urethral plate is ≥6 mm, tubularized incised plate (TIP) urethroplasty will be performed, whereas if the width of the urethral plate is \<6 mm, the onlay island flap (ONLAY) technique will be performed. When the urethral plate can not be preserved after degloving, transverse preputial island flap urethroplasty (Duckett) will be performed.
Study: NCT04783142

Intervention type: OTHER
Group type: OTHER
Intervention: High-fiber, low-protein diet
Description: Diet will consist of at least 15g fiber above baseline and less than 10% of calories from protein.

Intervention type: OTHER
Group type: OTHER
Intervention: Low-fiber, high-protein diet
Description: Diet will consist of less than 15g fiber and greater than 18% of calories from protein
Study: NCT06779994

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental phase of this study will last 8 weeks and each subject will have four visits (day 0, week 1, week 4 and week 8).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The experimental phase of this study will last 8 weeks and each subject will have four visits (day 0, week 1, week 4 and week 8).
Study: NCT06780774

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine, Vitamins, Minerals and Botanical Blend
Description: Blend containing 120mg of caffeine, vitamins, minerals and botanical extracts in capsule form.~Other Names: Active Treatment
Study: NCT04075370

Intervention type: OTHER
Intervention: Neuropsychological Testing
Description: Measure cognition function and cognitive reserve in patients before, during and after radiation therapy using cumulative scores of Hollingshead Index, North American Adult Reading Test, HVLT-R, TMT A\&B and COWA over time.
Study: NCT05308186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory stimulation
Description: The patient will be exposed to music that he used to enjoy (from the family's or guardian's report) through headphones. In case no report is given, nature (brook) sounds will be streamed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory and tactile stimulations
Description: The patient will be exposed to music that he used to enjoy (from the family's or guardian's report, otherwise nature (brook) music will be streamed) through headphones combined with deep tissue massage will be given on the upper limbs.
Study: NCT05718180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal imaging
Description: To measure the difference between ultrasound parameters based on maternal position: to measure the variation of AoP (Angle of progression), MLA (Midline Angle), PAA(pubic arch angle expressed in grades) HSD (head-symphysis distance) HPD(head perineum distance) expressed in millimeters, in the supine position and kneeling squat position in the same woman during the expulsion phase, in the resting step and during the push.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transperineal imaging
Description: To measure the difference between ultrasound parameters based on maternal position: to measure the variation of AoP (Angle of progression), MLA (Midline Angle), PAA(pubic arch angle expressed in grades) HSD (head-symphysis distance) HPD(head perineum distance) expressed in millimeters, in the supine position and kneeling squat position in the same woman during the expulsion phase, in the resting step and during the push.
Study: NCT05013086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.48 GBq of 177Lu-AB-3PRGD2
Description: accepted intravenous injection of 177Lu-AB-3PRGD2
Study: NCT04852627

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brisk walking
Description: Walking
Study: NCT05532631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: The studied intervention will be percutaneous coronary angioplasty with drug eluting stent implantation. Percutaneous coronary intervention may be performed during one single procedure or during staged procedures. The decision will be left at the investigator choice. PCI will be performed using drug eluting stent exclusively. The techniques for bifurcation lesions and chronic total occlusion angioplasty will be left at the operator choice. The choice of the drug eluting stent used will be left at the operator's choice. Anti-platelet therapy will be given to all patients randomized to PCI. The choice of the anti-thrombotic regiment and its duration will be left at the investigator choice (after assessment of initial presentation, bleeding and ischemic risks) but will have to comply with the European Society of Cardiology guidelines.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting
Description: Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines
Study: NCT05475964

Intervention type: DEVICE
Group type: OTHER
Intervention: Endoscopic ultrasound
Description: Endoscopic ultrasound and biopsy intake of suspected lesions
Study: NCT06780774

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blend containing 17mg Marigold Extract and Brown rice flour. Other Names: Placebo Treatment
Study: NCT06780644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple combination cream
Description: 1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle.
Study: NCT06102148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF Group
Description: Exercise training and PNF training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Exercise training
Study: NCT05197062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-aticaprant
Description: 14C-aticaprant will be administered orally as capsule on Day 1.
Study: NCT05346367

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SRT
Description: SRT
Study: NCT04677517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modification of active microphone positioning
Description: Patient will pass the experimental tests described above with 3 different active microphone positions :~* on the cochlear implant processor;~* on the antenna~* in front of the external ear canal~Patient will pass the tests 1 week after each microphone position change, so that they can get used to the new position in their everyday life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPHERE protocol
Description: Patient's 3D localization in noise will be assessed thnks to a 3D localization system called SPHERE based on virtual reality.~Data from spatial hearing perception will be recorded in three-dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D (the 3d-D value), hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: French Matrix Test
Description: This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: The Speech, Spatial and Qualities of Hearing Scale short-form with 15 items (SSQ15) questionnaire is performed in order to evaluate auditory abilities of patients in different daily life situations.
Study: NCT05346367

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fSRT
Description: fSRT
Study: NCT05510973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced package for AHD care
Description: The enhanced package of AHD care includes CD4 and tuberculosis lipoarabinomannan (TB-LAM) tests and the initiation of patients on TB prophylaxis \[TPT and CPT\], offered through a hub-and-spoke facility system, with continuous quality improvement (QI)
Study: NCT06318416

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: urine spectrophotometry for rifampin absorbance
Description: All participants will received conventional weight-based TB therapy, standard of care for active TB disease. After enrollment, participants will be randomized to early Day 14 or delayed Day 21 dose modification of rifampin informed by urine spectrophotometry where absorbance is determined above or below a threshold. Below a threshold, single tablets of rifampin are added to conventional fixed drug combination standard of care, above a threshold, no additional rifampin is added. Dose adjustment of rifampin may be up to \~30mg/kg and will be continued through day-56.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: urine spectrophotometry for rifampin absorbance
Description: All participants will received conventional weight-based TB therapy, standard of care for active TB disease. After enrollment, participants will be randomized to early Day 14 or delayed Day 21 dose modification of rifampin informed by urine spectrophotometry where absorbance is determined above or below a threshold. Below a threshold, single tablets of rifampin are added to conventional fixed drug combination standard of care, above a threshold, no additional rifampin is added. Dose adjustment of rifampin may be up to \~30mg/kg and will be continued through day-56.
Study: NCT04677517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Likert scale
Description: This subjective evaluation will be added to evaluate difficulties and self-confidence felt by participants during the SPHERE protocol and the French Matrix Test.
Study: NCT05214716

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FilmArray Pneumonia panel
Description: A rapid molecular diagnostic test designed to detect 27 bacterial and viral species and 6 major resistance genes from respiratory specimens.
Study: NCT06780644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple combination cream
Description: 1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing mometasone furoate 0.1%, hydroquinone 4%, tretinoin 0.05% at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle
Study: NCT06780696

Intervention type: DEVICE
Intervention: SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Description: Radiofrequency ablation of renal arterial sympathetic nerves
Study: NCT06335927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC-GEMOX+Cadonilimab+Regorafenib
Description: HAIC-GEMOX: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles in combination with Cadonilimab (6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W)
Study: NCT03947905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual visit
Description: Type of visit